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Topical 5-aminolevulinic acid is used for the fluores-
cence-based diagnosis and photodynamic treatment
of superficial precancerous and cancerous lesions of
the skin. Thus, we investigated the kinetics of
5-aminolevulinic acid-induced fluorescence and the
mechanisms responsible for the selective formation
of porphyrins in tumors in vivo. Using amelanotic
melanomas (A-Mel-3) grown in dorsal skinfold cham-
bers of Syrian golden hamsters fluorescence kinetics
were measured up to 24 h after topical application of
5-aminolevulinic acid (1%, 3%, or 10%) for 1 h, 4 h,
or 8 h by intravital microscopy (n J 54). Maximal
fluorescence intensity in tumors after 1 h application
(3% 5-aminolevulinic acid) occurred 150 min and after
4 h application (3% 5-aminolevulinic acid) directly
thereafter. Increasing either concentration of
5-aminolevulinic acid or application time did not yield
a higher fluorescence intensity. The selectivity of the
fluorescence in tumors decreased with increasing
application time. Fluorescence spectra indicated the
formation of protoporphyrin IX (3% 5-aminolevulinic
5-aminolevulinic acid (ALA), a precursor of heme, hasstimulated enormous interest as endogenous photosensit-izer for fluorescence diagnosis and photodynamic therapyof tumors after topical application. Bypassing the feedbackcontrol mechanism of the heme biosynthesis, the adminis-
tration of ALA induces the rather selective formation of porphyrins
in epithelial tissue (Kennedy et al, 1990; Fritsch et al, 1998). The
hydrophilic molecule ALA can be administered either systemically
(Grant et al, 1993; Regula et al, 1995; Fritsch et al, 1997) or
topically (Szeimies et al, 1994; Karrer et al, 1995; Fink-Puches et al,
1997). To avoid potential side-effects of the systemic administration
of ALA, topically applied ALA is preferred and is already used
clinically for the detection of occult neoplasms by means of the
induced fluorescence (Kriegmair et al, 1994; Leunig et al, 1996)
and for the treatment of different malignancies by means of the
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acid, 4 h; n J 3). The simultaneous application of
5-aminolevulinic acid (3%, 4 h) and glycine (20 mM
or 200 mM; n J 10) reduced fluorescence in tumor
and surrounding host tissue significantly. In contrast,
neither decreasing iron concentration by desferriox-
amine (1% and 3%; n J 10) nor inducing tetrapyrrole
accumulation using 1,10-phenanthroline (7.5 mM;
n J 5) increased fluorescence in tumors. The satura-
tion and faster increase of fluorescence in the tumor
together with a reduction of fluorescence by the
application of glycine suggests an active and higher
intracellular uptake of 5-aminolevulinic acid in tumor
as compared with the surrounding tissue. Shorter
application (1 h) yields a better contrast between tumor
and surrounding tissue for fluorescence diagnosis. The
additional topical application of modifiers of the heme
biosynthesis, desferrioxamine or 1,10-phenanthroline,
however, is unlikely to enhance the efficacy of topical
5-aminolevulinic acid–photodynamic therapy at least
in our model. Key words: amelanotic melanoma/fluorescence
kinetics/protoporphyrin/topical application. J Invest Derma-
tol 112:723–728, 1999
induced porphyrins (Kennedy and Pottier, 1992; Grant et al, 1993;
Wolf et al, 1993; Lui et al, 1995; Regula et al, 1995; Fromm et al,
1996; Fink-Puches et al, 1997, 1998; Gossner et al, 1998). The
major advantage of the so-called endogenous photosensitizer ALA
is the unique selectivity of the induced porphyrins not achieved
with other sensitizers up to now. Whether the selectivity is due to
an increased intracellular uptake, an increased porphyrin synthesis
or a reduced activity of the enzyme ferrochelatase is not clear.
Using the amelanotic melanoma of the hamster growing in a
transparent dorsal skinfold chamber the pharmacokinetics of ALA-
induced fluorescence in vivo following systemic administration of
ALA were determined and revealed that the tumor selectivity is
not due to a reduced activity of the enzyme ferrochelatase (Fritsch
et al, 1998; Abels et al, 1994). To elucidate the mechanism of
selectivity of the ALA-induced porphyrins and perhaps to increase
the selectivity we investigated the effects of the amino acid
glycine (Richards and Scott, 1961) as well as of the iron chelator
desferrioxamine (Fijan et al, 1995; Berg et al, 1996) and of the
inducer of tetrapyrroles 1,10-phenanthroline (Rebeiz et al, 1996)
on ALA-induced fluorescence in vivo.
MATERIALS AND METHODS
Animal and tumor model Experiments were performed using male
Syrian golden hamsters (60–80 g body weight) fitted with titanium dorsal
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skinfold chambers (n 5 82). The animals were housed in single cages and
had free access to food and water. Twenty-four hours after chamber
preparation 2 3 105 cells of the amelanotic melanoma of the hamster
(A-Mel-3) were implanted into each chamber when they did not show
any macroscopic sign of inflammation (for details see: Endrich et al, 1980;
Asaishi et al, 1981). The host tissue consists of a thin striated skin muscle
and underlying subcutaneous adipose tissue, dermis, and epidermis (Abels
et al, 1994). Six to 8 d later fluorescence microscopy and spectroscopy
were performed, when a functioning tumor microcirculation was established
(mean tumor diameter 4–6 mm). All surgical procedures were performed
under pentobarbital anesthesia (50 mg per kg body weight intraperitoneal;
Nembutal, Sanofi-LEVA, Hanover, Germany). The animals tolerated the
chamber well and showed no signs of discomfort.
Chemicals ALA hydrochloride (Medac, Hamburg, Germany) was dis-
solved in distilled water and buffered to pH 7.4. The solution was prepared
freshly in concentrations of 1%, 3%, or 10% at a temperature of 32°C.
Before the topical application of ALA solution for 1 h, 4 h, or 8 h the
animals were randomly assigned to each group. The ALA solution (100 µl)
was applied to each preparation, which was then covered tightly using an
adhesive foil (Opraflex, Lohmann GmbH, Neuwied, Germany) to avoid
drying of the chamber. At the end of the application time ALA was
removed and the chamber was rinsed using physiologic saline. For
simultaneous application of ALA and glycine 3% ALA and an equimolar
(20 µM) or a 10-fold higher concentration (200 µM) of glycine (Sigma,
St Louis, MO) were prepared as described above and applied to the
chamber. To reduce the iron concentration in the tissue desferrioxamine
(1% or 3%) was added 1 h prior to and removed before the application of
ALA (3%, 4 h). The tetrapyrrole modulator 1,10-phenanthroline (7.5 mM)
was added simultaneously because it acts as an enhancer of porphyrin
accumulation upon the exogenous application of ALA (3%, 4 h). The
fluorescence intensity was recorded thereafter.
In vivo fluorescence microscopy and spectroscopy For intravital
fluorescence microscopy of tumor and surrounding host tissue the awake,
chamber-bearing hamster was immobilized in a Perspex tube on a custom-
made stage (Effenberger, Munich, Germany) under a Leitz microscope
(Leitz, Munich, Germany, type 307-143003/51466) in the dark. For
subtraction of autofluorescence, intravital microscopy was performed prior
to the topical application of ALA. After application and removal of ALA
the chamber was occluded with a new coverglass. At 1, 15, 30, 45, 60,
90, 120, 150, 180, 240, 300, and 360 min and 24 h following application
(p.a.) ALA-induced fluorescence was measured in tumor and surrounding
host tissue. ALA-induced porphyrins were excited for 2 s with a power
density of 200–300 µW per cm2 and at a wavelength of 355–425 nm
(HBO mercury lamp, 100 W). Fluorescence was detected above 610 nm
and recorded by a silicon-intensified target video camera (C 2400–08,
Hamamatsu, Herrsching, Germany). Fluorescence images were acquired
using a digital image analysis system and stored on a hard disk (IBAS 2000,
Kontron, Eching, Germany). Spatial inhomogeneities of light or camera
were compensated by shading correction. Tissue autofluorescence was
subtracted and fluorescence intensity was measured densitometrically off-
line. Fluorescence values are given in percentage of the solid fluorescence
reference signal (Impregum F, Seefeld, Germany) inserted into each
chamber. The geometric resolution of all images was 512 3 512 pixels by
a densitometric resolution of 256 gray values. To determine ALA-induced
fluorescence in tumor and surrounding host tissue, regions of interest
(50 3 50 µm2) were chosen in a transillumination image prior to ALA
application. These region of interest did not overlay larger blood vessels.
Vertical cryostat sections did not show any fluorescence intensity gradient
from the surface to the basis of the chamber indicating a rather homogeneous
penetration of ALA in the tissue (data not shown).
Fluorescence spectroscopy was performed using an intensified optical
multichannel analyzer (O/SMA 3, Spectroscopy Instruments, Gilching,
Germany) as described previously (Abels et al, 1994). Fluorescence emission
spectra were determined in vivo from tumor and surrounding host tissue
shortly after 4 h of topical application of 3% ALA.
Statistics Statistical analysis of the data was performed using the paired-
t-test for related samples (Sigma Stat-Computer program, Jandel Scientific,
Erkrath, Germany). Differences were considered significant if p , 0.05.
RESULTS
Time- and concentration-dependent fluorescence kinetics
The fluorescence kinetics of ALA-induced porphyrins are shown
in Figs 1–3. After 1 h application of ALA all groups showed a
Figure 1. Fluorescence kinetics of endogenously formed porphyrins
in tumor and host tissue after topical application of 1%, 3%, and
10% ALA solution for 1 h. Mean 6 SEM; *p , 0.05, tumor versus host
tissue; n 5 6.
similar increase of the fluorescence intensity in the tumor and the
surrounding host tissue, which was faster in the tumor as compared
with the surrounding host tissue (Fig 1). Maxima in tumor (1%
ALA, 94% 6 16%; 3% ALA, 129% 6 26%; 10% ALA, 117% 6 23%)
were measured 150 min after end of application (1 h). After
application for 4 h (Fig 2) the maximal fluorescence intensity in
the tumor was measured 15 min p.a. (1% ALA, 80% 6 16%),
60 min p.a. (3% ALA, 215% 6 47%), or 15 min p.a. (10% ALA,
195% 6 81%). A concentration of 10% ALA did not increase the
maximal fluorescence intensity as compared with 3% ALA following
4 h application, whereas an application of 4 h yielded a significantly
higher fluorescence intensity as compared with 1 h using either
3% or 10% ALA. The maximal fluorescence intensity following
8 h application was measured immediately thereafter for all concen-
trations (1% ALA, 26% 6 7%; 3% ALA, 174% 6 34%; 10% ALA,
228% 6 42%) (Fig 3). Interestingly, the fluorescence intensity of
the surrounding host tissue exceeded that measured in tumors after
8 h application and 1% ALA over the entire observation period.
In all other groups the fluorescence intensity was always significantly
higher in tumor – at least during the first hour after application.
Moreover, there was no statistically significant difference of the
fluorescence intensity measured in the surrounding host tissue
regarding application time or concentration. Twenty-four hours
after topical application hardly any fluorescence was detectable in
all groups neither in tumor nor in surrounding host tissue.
For optimal photodynamic therapy using this tumor model the
tumor/host tissue fluorescence ratio was calculated for the different
groups. Maxima of each group are presented in Table I. The
VOL. 112, NO. 5 MAY 1999 KINETICS OF ALA-INDUCED PORPHYRINS 725
Figure 2. Fluorescence kinetics of endogenously formed porphyrins
in tumor and host tissue after topical application of 1%, 3%, and
10% ALA solution for 4 h. Mean 6 SEM; *p , 0.05, tumor versus host
tissue; n 5 6.
highest ratios were found already after 1 h of application independent
from the concentration applied (1% ALA, 22:1; 3% ALA, 30:1;
10% ALA, 30:1). By increasing the application time (4 h and 8 h)
the ratio between tumor and surrounding tissue could not be
improved. Moreover, there is a tendency that the fluorescence
ratio as indicator of the selectivity of ALA-induced porphyrins is
decreasing with increasing application time.
Induction of protoporphyrin IX (PPIX) by ALA as measured
by means of fluorescence spectroscopy Emission spectra of
the tumor and surrounding host tissue were registered 30 min
following 4 h application and 3% ALA, at the time the maximal
fluorescence ratio was found for this group. The emission bands
show maxima at 637 and 704 nm in tumor as well as host tissue
(spectra not shown). These peaks indicate the presence of PPIX.
Effects on ALA-induced fluorescence by glycine, desferriox-
amine, or 1,10-phenanthroline The simultaneous application
of ALA (3%) and the amino acid glycine (20 µM 5 equimolar
concentration) reduced the ALA-induced fluorescence (36%) signi-
ficantly in tumor as compared with ALA alone (100%) (Fig 4B).
By increasing the glycine concentration (200 µM) the induction
of fluorescence by ALA (22%) was further significantly reduced
(Fig 4C). The intensity of the ALA-induced fluorescence in the
host tissue was also affected but to a lesser degree. Thus, the
simultaneous application of ALA and the amino acid glycine
interferes with the formation of porphyrins in tumor and
surrounding host tissue.
The fluorescence intensity in the surrounding normal tissue
increased following application of desferrioxamine (3%) and there
Figure 3. Fluorescence kinetics of endogenously formed porphyrins
in tumor and host tissue after topical application of 1%, 3%, and
10% ALA solution for 8 h. Mean 6 SEM; *p , 0.05, tumor versus host
tissue; n 5 6.
Table I. Maximal tumor/host tissue fluorescence ratio
(time after application)
Application time ALA 1% ALA 3% ALA 10%
1 h 22:1 (60 min) 30:1 (15 min) 30 : 1 (1 min)
4 h 5:1 (60 min) 10:1 (30 min) 10 : 1 (15 min)
8 h 0.7:1 (15 min) 4:1 (1 min) 16 : 1 (15 min)
was no statistically significant difference as compared with the
tumor (Fig 5A, B). Interestingly, the preincubation with desferriox-
amine in a concentration of either 1% or 3% reduced significantly
the ALA-induced fluorescence in the tumor. Moreover, adding the
tetrapyrrole modulator 1,10-phenanthroline and ALA (3%) an
increase of the fluorescence intensity as compared with ALA
alone was not observed neither in tumor nor surrounding host
tissue (Fig 5C).
DISCUSSION
Intravital fluorescence microscopy and spectroscopy of the amelan-
otic melanoma implanted in the dorsal skinfold chamber can be
used successfully to determine the kinetics of intravenously applied
photosensitizers, which provide the basis for optimal fluorescence
diagnosis or photodynamic therapy in this model (Leunig et al,
1993; Abels et al, 1994). In the current investigation we used this
model for the respective analysis following topical application of
ALA and to elucidate the so far unknown mechanism of selectivity
of the ALA-induced porphyrins, as previous experiments did not
reveal a reduced activity of the ferrochelatase in this model (Abels
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Figure 4. Fluorescence kinetics of porphyrins in tumor and host
tissue following the simultaneous application of ALA or glycine.
(A) ALA 3%, 4 h; (B) 20 µM glycine; (C) 200 µM glycine. Application
to ALA without glycine served as control. There is a statistically significant
decrease of the fluorescence intensity in the tumor following the application
of glycine (20 µM and 200 µM) except at 24 h after application.
et al, 1994). The concentrations administered for this investigation
were chosen according to topically applied doses for fluorescence
diagnosis of bladder tumors (3% ALA) (Kriegmair et al, 1994) or
for photodynamic therapy of skin tumors (10% ALA) (Szeimies
et al, 1995).
The maximal fluorescence intensity was found shortly after 4 h
application of 3% ALA, which did not increase by adding a higher
concentration (10%) or by longer application (8 h) indicating a
saturation of the intracellular uptake or porphyrin formation in the
amelanotic melanoma (Figs 1–3). This finding is in accordance
with an earlier study using this model following intravenous
administration of ALA (Abels et al, 1994). The increase of fluores-
cence in tumor is faster as compared with surrounding host tissue
following topical application indicating a faster uptake or increased
heme biosynthesis and not a reduced activity of the ferrochelatase –
a similar activity of the ferrochelatase in the amelanotic melanoma
as compared with skin was shown recently (Fritsch et al, 1998). A
faster increase was also observed in actinic keratoses and squamous
cell carcinomas of mice as compared with normal skin (Van der
Veen et al, 1996). In that study, however, only a single concentration
(20%) and a single application time (4 h) were studied (Van der
Veen et al, 1996). The maximal fluorescence intensity was measured
6 h after the end of the 4 h application time of ALA, whereas in
our study it was found already 3 h after the 1 h application and
Figure 5. Fluorescence kinetics of ALA-induced porphyrins in
tumor and host tissue following application of ALA (3%, 4 h)
desferrioxamine (1%), desferrioxamine (3%), or 1,10-phenan-
throline. (A) Desferrioxamine 1%; (B) desferrioxamine 3%; (C) 1,10-
phenanthroline. Interestingly, there is a significant decrease of the
fluorescence intensity in the tumor following application of desferrioxamine
(A, B) and a slight increase of the fluorescence in the surrounding tissue
(B). The addition of 1,10-phenanthroline (C) at a concentration of 7.5 mM
showed no effect on the time course of ALA-induced fluorescence neither
in the tumor nor in surrounding tissue.
30 min after the 4 h application. This difference can be explained
by the lack of an overlying stratum corneum in our model. Thus,
it is not surprising that a similar time course was measured in
bladder tumors following 4 h of intravesical instillation and a
decrease following 6 h of instillation (Xiao et al, 1998). In the
orthotopic bladder tumor model used, however, the selectivity of
ALA-induced fluorescence was reduced following topical applica-
tion as compared with intravenous injection. The fluorescence
intensity in the amelanotic melanoma was 30 times higher (3%
ALA, 1 h) (Table I) as compared with surrounding host tissue
exceeding the tumor/surrounding tissue ratios measured so far by
Van der Veen et al (1996) in squamous cell carcinomas and skin as
well as by Iinuma et al (1995) in a bladder tumor and surrounding
urothelium. This is probably due to the underlying striated skin
muscle in our model forming less porphyrins as tissue of epithelial
origin. Nevertheless, it is noteworthy that in our model the
selectivity of the induced porphyrins as indicated by the tumor/
surrounding host tissue fluorescence ratio was decreasing with the
longer application time (Table I), which was similar to the
orthotopic bladder tumor model (Xiao et al, 1998). Thus, shorter
application times of ALA seem to yield a better contrast between
normal and neoplastic tissue due to the faster increase of the ALA-
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induced fluorescence in tumor as compared with the surrounding
host tissue. This was also observed clinically by us in basal cell
carcinomas and surrounding skin following topical application of
20% ALA in an W/O emulsion (Ackermann et al, 1998). Moreover,
using a three-compartment model comparable rate coefficients
were calculated for the amelanotic melanoma as well as for human
basal cell carcinomas (unpublished data).
Comparing the different routes of administration of ALA, either
intravenously as investigated previously (Abels et al, 1994) or
topically as in this study the kinetics after 1 h application of ALA
are similar as compared with those after intravenous injection of
500 mg per kg. Moreover, the maximal fluorescence intensity of
neoplastic tissue reached in this model is µ190% following either
topical or systemic administration. Taking these data into account
a topical application might be more efficient as an uptake of ALA
in other organs, e.g., liver, kidney, or a generalized photosensitivity
and other systemic side-effects does not occur. The selectivity
following topical application, however, might be slightly reduced
as compared with the intravenous administration in our model,
but not as marked as observed in an orthotopic bladder tumor
model (Xiao et al, 1998).
The recording of the fluorescence spectra in tumor and sur-
rounding host tissue revealed the characteristic emission bands of
PPIX (Dailey and Smith, 1984; Bedwell et al, 1992). Additional
peaks at 618 nm and 678 nm as seen after intravenous injection of
ALA in this model (Abels et al, 1994) did not occur following
topical application suggesting the formation of the porphyrin
following intravenous injection emitting these bands elsewhere in
the organism but not in tumor or surrounding host tissue.
Selective ALA-induced accumulation of porphyrins is suggested
to be a result of a reduced activity of the enzyme ferrochelatase as
shown in hepatomas (Dailey and Smith, 1984) and colon carcinomas
of rats (Van Hillersberg et al, 1992). This enzymatic defect and also
reduced intracellular iron levels (Rittenhouse-Diakun et al, 1995)
are discussed as mechanisms for the selective fluorescence in the
tumor as compared with surrounding host tissue. As indicated by
the faster and higher porphyrin accumulation in our model follow-
ing either intravenous or topical application the selective accumula-
tion of porphyrins is mainly due to an increased uptake and not
due to the reduced activity of the enzyme ferrochelatase (Abels
et al, 1994, 1997; Fritsch et al, 1998). In addition, the fact that
ALA-induced fluorescence could be saturated after systemic or
topical application supports this hypothesis. Studies concerning the
intracellular uptake of ALA were conducted in Saccharomyces cerevisiae
indicating an active ALA uptake system in this eukaryotic model
(Moretti et al, 1993, 1995). This has already been confirmed in vitro
using a melanoma cell line showing that ALA is transported via an
active transport mechanism and not via diffusion (Kalka et al, 1997).
Major effects are not described on the uptake of ALA in mammalian
cells by amino acids like γ-aminobutyric acid or glutamic acid with
a similar chemical structure such as ALA (Washbrook et al, 1997).
It has been shown, however, that the amino acid glycine given
orally to patients suffering from acute porphyria increases the rate
of excretion of ALA in their urine (Richards and Scott, 1961).
Therefore, we assumed that the simultaneous application of ALA
and glycine in equimolar concentration should reduce the ALA-
induced fluorescence in our model. As supposed the simultaneous
application of ALA and glycine yielded a reduction – probably
concentration dependent – of ALA-induced fluorescence in tumor
and surrounding host tissue (Fig 4). This finding suggests a glycine-
mediated inhibition of the intracellular uptake of ALA into the
amelanotic melanoma and to a significant lower degree into the
surrounding host tissue in vivo. Knowing that this hypothesis has
to be confirmed by the appropriate in vitro experiments we suggest
that ALA and glycine seem to share the same mechanism of
internalization into amelanotic melanoma cells. This finding is
important regarding the unique selectivity of ALA-induced porphy-
rins in neoplastic tissue, in also making use of it for therapeutic
strategies.
To increase the accumulation and perhaps the selectivity of the
ALA-induced porphyrins after topical application of ALA the iron
chelator desferrioxamine (1% or 3%) was added 1 h prior to ALA.
Desferrioxamine is a specific chelator for iron and may thus reduce
the metabolization of PPIX into heme. Surprisingly, there was a
decrease of the fluorescence intensity in the tumor following either
concentration and the application of the higher concentration
yielded even a slight increase of the fluorescence intensity in the
surrounding tissue (Fig 5B) thus reducing the selectivity. This
finding is in contrast to in vitro studies which showed an increased
PPIX production in carcinoma cells using desferrioxamine and
ALA (Ortel et al, 1993; Berg et al, 1996; Tan et al, 1997). Similar
to those findings Peng et al (1996) observed an enhanced PPIX
formation and the iron chelator CP94 given intraperitoneally to
rats seems also to be effective in increasing ALA-induced PPIX in
the bladder as compared with ALA alone (Chang et al, 1997). In
these in vivo studies, however, only normal tissue, normal mouse
skin, and normal rat urothelium, respectively, were investigated.
And this finding is in accordance with our results as there was also
an increase of ALA-induced fluorescence in the surrounding normal
tissue following application of desferrioxamine (3%) (Fig 5B).
This pronounced increase in the surrounding tissue reduced the
selectivity of ALA-induced fluorescence following application of
desferrioxamine in vivo as already speculated by Berg et al (1996)
according to their in vitro findings.
As reported by Rebeiz et al (1996) the simultaneous injection
of 1,10-phenanthroline (7.5 mM) yielded a higher porphyrin
accumulation in a mice fibrosarcoma model following intratumoral
application of ALA. As shown in Fig 5C there was no effect on
ALA-induced fluorescence when applied topically neither in the
tumor nor in the surrounding host tissue in our model. As it is
supposed that 1,10-phenanthroline interacts rather unspecifically
with enzymes of the heme biosynthesis due to its chemical structure,
we also expected an increase of the ALA-induced fluorescence
during the observation time of 6 h (Rebeiz et al, 1996). In the
study by Rebeiz et al it was already noticed that the accumulation
of PPIX after application of ALA/1,10-phenanthroline was signi-
ficantly higher in single cell suspensions (7-fold increase versus ALA
alone) as compared with solid tumors (2-fold increase versus ALA
alone). Thus, the increase of ALA-induced fluorescence in the
amelanotic melanoma due to the addition of 1,10-phenanthroline
might be not significant enough to be detected by our set up.
To elucidate the underlying mechanisms resulting in the unique
selectivity of ALA-induced fluorescence the intracellular uptake of
ALA should be characterized and further investigations in vivo
should focus on whether the faster and higher accumulation of
porphyrins in tumors is due to an increased ALA uptake or just
reflects an increased porphyrin formation due to a higher demand
of tumors for heme.
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